Jump directly to the page contents

Health

Due to increasing life expectancy and declining birth rates, the percentage of old people in the population continuously rises and poses ever growing challenges to our society and our health system.

Chronic common and old age diseases such as cardiovascular and metabolic diseases, cancer, diabetes, lung diseases, degenerative diseases of the nervous system or chronic inflammatory diseases as well as them being influenced by environmental factors and life style continue to grow in relevance and, in addition to research on infectious diseases, stand at the center of the Helmholtz health research.

Scientists from those Helmholtz Centers involved in the research field Health study causes and emergence of these often complex diseases and on this basis develop new strategies for early detection, prevention, diagnosis and therapy. In recent years, the participating centers have increasingly drawn on new forms of collaboration with strong partners from medical schools, universities, other research organizations and industry. To enable the fastest possible transfer of promising approaches from basic research into clinical application, the Helmholtz Health Centers currently are developing Translation Centers at their sites in close interaction with local partners from university medicine.

Powerful and sustainable structures for networking research competencies of extramural and university health research are being created for important disease fields. Thus 2009 saw the establishment of the German Center for Neurodegenerative Diseases e. V. (DZNE) with its core site in Bonn as well as the German Center for Diabetes Research e.V. (DZD), members of which are the Helmholtz Zentrum München, university partners and institutes from the Leibniz Association. Further centers, amongst them the German Consortium for Translational Cancer Research, coordinated by the German Cancer Research Centre DKFZ, will be put out to tender in 2010.

One of the future key tasks aims to advance German health research by integrating the entire expertise and competence at the Helmholtz Health Centers, university hospitals and other research organizations to create strong strategic partnerships. The biomedical knowledge gain for socially important disease fields is in the foreground and, bundled in consortiums or networks, will yield concrete clinical applications and thus strengthen the German health research with lasting effect and reposition it internationally.

Highlights

  • Health, Matter

    The successful development of the mRNA active ingredient highlights the vital role basic research plays in applications.

  • Health

    Five questions for Sabrina Geisberger, biochemist at the Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC).

  • Health

    Luka Cicin-Sain from the Helmholtz Centre for Infection Research explains why Omicron is possibly a game changer, which variants we can expect in the future, and what we can do about them.

  • Health

    The Corona pandemic has helped the development of mRNA vaccines make a breakthrough. But this technology was originally developed to treat cancer. In an interview, Dirk Jäger explains when we can…

  • Health

    How booster vaccination works and why it also protects us against Omicron: An interview with virologist Ulrike Protzer, Institute Director at Helmholtz Munich.

  • Health

    Since the end of June 2021, the delta variant of the coronavirus has also dominated the pattern of infection in Germany. What do we know about the corona variant?

Contact

Michael Baumann

Program spokesperson Cancer Research
Deutsches Krebsforschungszentrum

Juliane Kampe

Chief Research Manager Health
Helmholtz Association

As curious as we are? Discover more.